FDA clears Alzheimer’s blood test: a game changer for biomarker-driven trials

AbbVie submitted an NDA to the FDA following Ph3 data of Tavapadon targeting Parkinson’s

BMS granted FDA Fast Track Designation for BMS-986446 - an anti-microtubule binding region tau antibody currently in Ph2 targeting Alzheimer’s

C2N Diagnostics submitted regulatory filing to the FDA for their Alzheimer’s blood test

Herantis Pharma announced positive topline Ph1b data evaluation HER-096 targeting PD

Yongchang Qiu

Founder & Chief Executive Officer Lysoway Therapeutics

Thursday 5th February 2026

Lysosomal Ion Channels as a New Therapeutic Class in Neurodegeneration: Advancing TRPML1 and TMEM175 Small-Molecule Agonists

1:30 pm

Scientific and genetic rationale for targeting lysosomal ion channels in age-related neurodegenerative diseases (AD and PD)
Development considerations, challenges, and translational promises in advancing a highly brain-penetrant, Phase 1–ready TRPML1 small-molecule agonist
Emerging preclinical data of a development candidate TMEM175 agonist for Parkinson’s disease